ONCY News and Press, Oncolytics Biotech Inc. From 09/20/19

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market...

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will pr...

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will ...

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it will host a conference call and live webcast for Analysts and In...

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 16, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the closing of its previously anno...

This is a correction to our previous announcement to highlight currency of the pricing SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC) (the “Company”), currently developing pelareorep, an...

Thinly traded nano cap Oncolytics Biotech (NASDAQ: ONCY ) slumps  29%  premarket on increased volume in response to its public offering of ~4.6M common shares and accompanying five-year warrants to purchase up to the same number of shares at a combined price of $0.81. More news...

SAN DIEGO, CA & CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the pricing of its previously annou...

Oncolytics Biotech (NASDAQ: ONCY ): Q2 GAAP EPS of -$0.26 misses by $0.07 . More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, CA and CALGARY, AB, August 13, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it intends to offer to sell common shares and warrants to purchase comm...